Cardiff Oncology, Inc. (CRDF)
- Previous Close
4.3600 - Open
4.3600 - Bid 4.1500 x 400
- Ask 4.2100 x 700
- Day's Range
4.0600 - 4.4197 - 52 Week Range
0.9400 - 6.4200 - Volume
699,032 - Avg. Volume
1,856,164 - Market Cap (intraday)
186.304M - Beta (5Y Monthly) 1.97
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.50
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
www.cardiffoncology.comRecent News: CRDF
Performance Overview: CRDF
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDF
Valuation Measures
Market Cap
186.30M
Enterprise Value
113.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
381.77
Price/Book (mrq)
2.67
Enterprise Value/Revenue
232.85
Enterprise Value/EBITDA
-2.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.69%
Return on Equity (ttm)
-47.07%
Revenue (ttm)
488k
Net Income Avi to Common (ttm)
-41.47M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
74.82M
Total Debt/Equity (mrq)
3.08%
Levered Free Cash Flow (ttm)
-18.01M
Research Analysis: CRDF
Company Insights: CRDF
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CRDF
Daily – Vickers Top Buyers & Sellers for 09/23/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/14/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 06/18/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 06/17/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.